Kodiak Sciences (KOD) Capital Expenditures (2017 - 2026)
Kodiak Sciences' (KOD) quarterly Capital Expenditures came in at $942000.0 in Q1 2026, up 248.89% YoY from $270000.0 in Q1 2025, and up 2090.7% on a QoQ basis from $43000.0 in Q4 2025.
Analysis
Kodiak Sciences (KOD) Capital Expenditures (2017 - 2026) Analysis & Trends
Kodiak Sciences (KOD) has 10 years of Capital Expenditures data on file, last reported at $942000.0 in Q1 2026.
- Quarterly Capital Expenditures rose 248.89% year-over-year to $942000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.2 million (up 89.09% YoY) and the FY2025 annual result came in at $506000.0, up 34.93% from the prior year.
- Capital Expenditures improved to $942000.0 in Q1 2026, from $43000.0 in the prior quarter.
- In the past five years, Capital Expenditures ranged from a high of $27.5 million in Q4 2023 to a low of $22000.0 in Q1 2024.
- A 5-year average of $4.7 million and a median of $270000.0 in 2025 frame the typical range for Capital Expenditures.
- Annual changes were most pronounced in 2022 — Capital Expenditures soared 1311.48% — and 2024, when it sank 99.82%.
- Tracing KOD's Capital Expenditures over 5 years: stood at $3.1 million in 2022, then soared by 797.29% to $27.5 million in 2023, then plunged by 99.55% to $124000.0 in 2024, then plunged by 65.32% to $43000.0 in 2025, then soared by 2090.7% to $942000.0 in 2026.
- The last three Capital Expenditures figures came in at $942000.0 (Q1 2026), $43000.0 (Q4 2025), and $60000.0 (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 37.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 2.29 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 25.02 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 34.68 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 251.02 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 6.26 Mn |
| 10 | Kodiak Sciences | 2.21 Bn | 2.21 Bn | - | 352,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 352,000.00 |
| Mar 31, 2026 | 942,000.00 |
| Dec 31, 2025 | 43,000.00 |
| Sep 30, 2025 | 60,000.00 |
| Jun 30, 2025 | 133,000.00 |
| Mar 31, 2025 | 270,000.00 |
| Dec 31, 2024 | 124,000.00 |
| Sep 30, 2024 | 180,000.00 |
| Jun 30, 2024 | 49,000.00 |
| Mar 31, 2024 | 22,000.00 |
| Dec 31, 2023 | 27.48 Mn |
| Sep 30, 2023 | 226,000.00 |
| Jun 30, 2023 | 1.47 Mn |
| Mar 31, 2023 | 12.17 Mn |
| Dec 31, 2022 | 3.06 Mn |
| Sep 30, 2022 | 8.27 Mn |
| Jun 30, 2022 | 8.23 Mn |
| Mar 31, 2022 | 17.46 Mn |
| Dec 31, 2021 | 8.43 Mn |
| Sep 30, 2021 | 4.83 Mn |